| 2.29 0.065 (2.92%) | 05-22 15:09 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.97 | 1-year : | 3.25 |
| Resists | First : | 2.54 | Second : | 2.78 |
| Pivot price | 2.44  |
|||
| Supports | First : | 2.15 | Second : | 1.79 |
| MAs | MA(5) : | 2.26 |
MA(20) : | 2.45 |
| MA(100) : | 2.71 |
MA(250) : | 2.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 8.2 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 3.79 | Low : | 2.06 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NSPR ] has closed above bottom band by 25.5%. Bollinger Bands are 21.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.28 - 2.29 | 2.29 - 2.31 |
| Low: | 2.16 - 2.17 | 2.17 - 2.19 |
| Close: | 2.2 - 2.22 | 2.22 - 2.25 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Mon, 12 May 2025
InspireMD (NSPR) Price Target Reduced, FDA Approval Timeline Adj - GuruFocus
Sat, 10 May 2025
InspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Call Transcript - Insider Monkey
Fri, 09 May 2025
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
Wed, 30 Apr 2025
InspireMD's Revolutionary Stroke Prevention Technology Takes Center Stage at Major Healthcare Conference - Stock Titan
Tue, 08 Apr 2025
InspireMD Expands Team: 299K Shares Granted to New Medical Device Experts - Stock Titan
Wed, 12 Mar 2025
Earnings call transcript: InspireMD Q4 2024 beats revenue forecast, stock rises - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 31 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 28.4 (%) |
| Held by Institutions | 42 (%) |
| Shares Short | 181 (K) |
| Shares Short P.Month | 240 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.94 |
| Profit Margin | 0 % |
| Operating Margin | -749.6 % |
| Return on Assets (ttm) | -58.2 % |
| Return on Equity (ttm) | -114 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.22 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -3.02 |
| PEG Ratio | 0 |
| Price to Book value | 2.41 |
| Price to Sales | 9.97 |
| Price to Cash Flow | -2.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|